Education
About Us
Working with TipRanks
Follow Us
MariMed Inc (TSE:MRMD)
:MRMD
MRMD Stock Chart & Stats
C$0.11
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.11
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.06 - C$0.48
Previous CloseN/A
Volume0.00
Average Volume (3M)46.35K
Market Cap
C$45.21M
Enterprise ValueC$123.99M
Total Cash (Recent Filing)C$8.88M
Total Debt (Recent Filing)C$100.09M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
May 13, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding397,882,750
10 Day Avg. Volume89,801
30 Day Avg. Volume46,354
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)2.33
Price to Sales (P/S)0.21
P/FCF Ratio5.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$0.34Price Target Upside208.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.04
Revenue Forecast (FY)C$217.86M
Bulls Say, Bears Say
Bulls Say
Market Penetration & Brand LeadershipHigh distribution penetration (~85% of dispensaries) and category-leading brands create durable shelf presence and customer recognition across core states. Strong placement reduces customer acquisition costs, supports wholesale scale, and helps defend pricing and share even amid pricing pressure.
Wholesale Channel DiversificationGrowing wholesale mix and geographic expansion (notably Illinois and Delaware) diversify revenue beyond retail, enabling higher-volume, asset-light growth and broader brand distribution. This reduces reliance on single-market retail volatility and supports margin recovery via scale and internalized brands.
Improved Cash Generation & EBITDA ConsistencyPositive free cash flow in 2025 combined with a multi-year streak of positive adjusted EBITDA demonstrates improving cash conversion and operational resilience. Sustainable cash generation supports reinvestment, debt servicing, and strategic flexibility versus peers with persistent negative cash flow.
Bears Say
Elevated Leverage & Equity ErosionSharp rise in leverage and a diminished equity base materially constrain financial flexibility and increase solvency risk. High leverage magnifies downside from continued losses, limits ability to fund capital projects organically, and raises refinancing and covenant exposure over the medium term.
Margin Compression And Sustained LossesSteady gross margin erosion and a return to operating losses indicate structural pricing pressure in mature markets. Persistent margin compression undermines profitability even as revenue scales, making it harder to convert sales into sustainable net income absent product mix or cost-structure improvements.
Capital-structure Dilution & New Senior ClaimsThe preferred-stock restructuring eases near-term cash need but introduced senior liquidation/dividend rights, promissory notes, and potential dilution. These changes increase future cash outflow commitments and subordinate common equity, constraining returns to shareholders and complicating long-term capital planning.
MariMed News
MRMD FAQ
What was MariMed Inc’s price range in the past 12 months?
MariMed Inc lowest stock price was C$0.06 and its highest was C$0.48 in the past 12 months.
What is MariMed Inc’s market cap?
MariMed Inc’s market cap is C$45.21M.
When is MariMed Inc’s upcoming earnings report date?
MariMed Inc’s upcoming earnings report date is May 13, 2026 which is in 58 days.
How were MariMed Inc’s earnings last quarter?
MariMed Inc released its earnings results on Mar 11, 2026. The company reported C$0.008 earnings per share for the quarter, beating the consensus estimate of -C$0.014 by C$0.022.
Is MariMed Inc overvalued?
According to Wall Street analysts MariMed Inc’s price is currently Undervalued.
Does MariMed Inc pay dividends?
MariMed Inc does not currently pay dividends.
What is MariMed Inc’s EPS estimate?
MariMed Inc’s EPS estimate is -0.01.
How many shares outstanding does MariMed Inc have?
MariMed Inc has 397,882,750 shares outstanding.
What happened to MariMed Inc’s price movement after its last earnings report?
MariMed Inc reported an EPS of C$0.008 in its last earnings report, beating expectations of -C$0.014. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MariMed Inc?
Currently, no hedge funds are holding shares in TSE:MRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MariMed Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$0.34 (208.69% Upside)
C$0.34 (208.69% Upside)
Insider Transactions
Bought Shares
Worth $4.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.40%
12-Months-Change
Fundamentals
Return on Equity
-29.77%
Trailing 12-Months
Asset Growth
-2.14%
Trailing 12-Months
Company Description
MariMed Inc
MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company offers cannabis genetics produce flowers and concentrates under the Nature's Heritage brand; cannabis-infused products in the form of chewable tablets and powder drink mixes under the brand Kalm Fusion; natural fruit chews under the Betty's Eddies brand; brownies, cookies, and other social sweets under the Bubby's Baked brand; and cannabidiol formulations under the Florance brand. It also licenses its brands and product formulations, as well as leases cannabis facilities. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.
MRMD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a cautiously optimistic tone: MariMed reported continued brand and wholesale momentum (category leadership, expanded penetration, wholesale growth, Delaware AU traction), maintained positive adjusted EBITDA streak, and executed balance sheet actions to improve flexibility. However, the company is facing notable margin and retail headwinds in mature markets (notably Illinois and Massachusetts), experienced declines in EBITDA and operating income YoY, and has limited near‑term cash reserves. Management emphasized disciplined cost control, asset‑light licensing expansion, and selective M&A, while acknowledging timing risk for new market contributions.View all TSE:MRMD earnings summariesMRMD Stock 12 Month Forecast
Average Price Target
C$0.34
▲(208.69% Upside)
Technical Analysis
Options Prices
Currently, No data available
---